Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.


Journal

International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 30 06 2019
accepted: 19 08 2019
pubmed: 25 8 2019
medline: 26 3 2020
entrez: 25 8 2019
Statut: ppublish

Résumé

The aim of this study is to evaluate the association between total testosterone density (TTD), defined as the ratio of serum TT to prostate volume (PV), and high tumor load (HTL) in low-risk prostate cancer (PCA) patients who underwent radical prostatectomy. Tumor load was defined as the percentage of prostate volume invaded by cancer (PPI-PCA) in the surgical specimen. Pathologic features including tumor upgrading, upstaging or positive surgical margins in the specimen defined unfavorable disease (UD). PSA, TT, PSA density (PSAD), TTD, percentage of biopsy positive cores (BPC), PV and body mass index (BMI). The association of factors with the risk UD and HTL was evaluated by statistical methods. The cohort included 144 consecutive low-risk PCA patients. Overall, 104 patients (72.2%) had at least one feature indicating UD. TTD was associated with BMI, TT, PSA, PV and PPI-PCA ≥ 20% defined as HTL. A higher PPI-PCA was associated with an increased risk of UD with a fair discriminant power (area under the curve, AUC = 0.775; p < 0.0001). Patients with PPI-PCA > 20% were considered the study group versus patients with a PPI-PCA < 20% (control group). BPC, PSAD and TTD were independently associated with the risk of HTL (PPI-PCA ≥ 20%) with receiver-operating characteristics (ROC) curves indicating the same discriminant power for BPC (AUC = 0.628; p = 0.013), PSAD (AUC = 0.611; p = 0.032) and TTD (AUC = 0.610; p = 0.032). Among low-risk PCA patients, TTD is associated with the risk of HTL, which is an independent predictor of UD and should be evaluated in the management of these patients.

Identifiants

pubmed: 31444696
doi: 10.1007/s11255-019-02263-6
pii: 10.1007/s11255-019-02263-6
doi:

Substances chimiques

Testosterone 3XMK78S47O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2169-2180

Références

Arch Pathol Lab Med. 2009 Oct;133(10):1568-76
pubmed: 19792046
Urology. 1998 Oct;52(4):631-6
pubmed: 9763083
J Urol. 1998 Dec;160(6 Pt 2):2418-24
pubmed: 9817395
Tumori. 2018 Mar-Apr;104(2):111-115
pubmed: 27791231
Oncotarget. 2017 Mar 14;8(11):18424-18434
pubmed: 27793023
J Clin Endocrinol Metab. 2008 Jul;93(7):2737-45
pubmed: 18270261
Minerva Urol Nefrol. 2018 Oct 03;:null
pubmed: 30298710
J Steroid Biochem Mol Biol. 2006 Jun;99(4-5):182-8
pubmed: 16621522
Urology. 1998 Mar;51(3):412-4
pubmed: 9510345
Int Urol Nephrol. 2016 Sep;48(9):1437-43
pubmed: 27170341
J Urol. 2003 Mar;169(3):969-73
pubmed: 12576824
J Urol. 1992 Mar;147(3 Pt 2):815-6
pubmed: 1371554
J Clin Oncol. 2005 Oct 20;23(30):7546-54
pubmed: 16234520
Transl Androl Urol. 2017 Jun;6(3):566-579
pubmed: 28725600
Minerva Urol Nefrol. 2019 Oct;71(5):516-523
pubmed: 31241272
Tumori. 2017 May 12;103(3):299-306
pubmed: 27716882
Urol Int. 2017;99(2):215-221
pubmed: 28245478
Urol Int. 2019 Jun 4;:1-8
pubmed: 31163438
Urol Int. 2018;100(3):251-262
pubmed: 29161715
BJU Int. 2013 May;111(5):753-60
pubmed: 23464824
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Int Urol Nephrol. 2013 Feb;45(1):121-7
pubmed: 23054323
Prostate. 1999 Feb 1;38(2):144-50
pubmed: 9973100
Asian J Androl. 2019 Jul 26;:null
pubmed: 31347517
Urol Int. 2018;101(1):38-46
pubmed: 29975957
Urol Int. 2017;98(1):32-39
pubmed: 27798942
Urol Int. 2016;96(4):470-8
pubmed: 26845458
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
J Urol. 2003 May;169(5):1670-5
pubmed: 12686805
Urol Oncol. 2016 Nov;34(11):482.e1-482.e4
pubmed: 27423822
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol. 2012 May;61(5):1019-24
pubmed: 22336380
Urol Int. 2016;97(1):32-41
pubmed: 26998904
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
Int Urol Nephrol. 2014 Oct;46(10):1935-40
pubmed: 24817520
J Clin Endocrinol Metab. 1976 May;42(5):979-82
pubmed: 1270587
J Robot Surg. 2019 Feb;13(1):83-89
pubmed: 29737495
Urol Int. 2017;99(2):207-214
pubmed: 28245480
J Urol. 2003 Jun;169(6):2289-92
pubmed: 12771773
BJU Int. 2012 Dec;110(11 Pt B):E667-72
pubmed: 22974446
J Urol. 2015 Feb;193(2):403-13
pubmed: 25260832

Auteurs

Antonio B Porcaro (AB)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy. drporcaro@yahoo.com.

Alessandro Tafuri (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Marco Sebben (M)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Tania Processali (T)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Marco Pirozzi (M)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Aliasger Shakir (A)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Nelia Amigoni (N)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Riccardo Rizzetto (R)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Matteo Brunelli (M)

Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Filippo Migliorini (F)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Salvatore Siracusano (S)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Walter Artibani (W)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH